Eur Rev Med Pharmacol Sci 2020; 24 (22): 11953-11959

DOI: 10.26355/eurrev_202011_23856

Procalcitonin is a predictor of disseminated intravascular coagulation in patients with fatal COVID-19

R. Asoğlu, H. Tibilli, A. Afşin, S. Türkmen, H.A. Barman, E. Asoğlu

Cardiology Department, Adıyaman University Training and Research Hospital, Adıyaman, Turkey. dr.asoglu@yahoo.com


OBJECTIVE: The coagulopathies that present with COVID-19 are thrombotic microangiopathy and disseminated intravascular coagulopathy (DIC). Procalcitonin (PCT) levels have been shown to be significantly increased in COVID-19 patients in comparison with healthy subjects/asymptomatic coronavirus-positive patients. In this report, our aim was to assess the associations of the PCT level with DIC and the severity of COVID-19 infection.

PATIENTS AND METHODS: In this cross-sectional, retrospective study, 71 consecutive patients with severe COVID-19 (21 with DIC and 50 without DIC) were enrolled in the study. The PCT level was obtained from hospital records.

RESULTS: The PCT level was significantly higher in the patients with DIC than in those without DIC [1.9 (0.6-14.5) vs. 0.3 (0.2-0.4) (ng/mL), p<0.01]. The PCT level showed a positive and significant correlation with DIC (r=0.382, p=0.001) and was an independent predictor of DIC in patients with severe COVID-19 (OR: 6.685, CI: 1.857-24.063, p<0.01).

CONCLUSIONS: In summary, the PCT level was increased in severe COVID-19 patients with DIC compared with those without DIC. An increased PCT level might suggest the presence of DIC and may help in predicting COVID-19 severity.

Free PDF Download

To cite this article

R. Asoğlu, H. Tibilli, A. Afşin, S. Türkmen, H.A. Barman, E. Asoğlu
Procalcitonin is a predictor of disseminated intravascular coagulation in patients with fatal COVID-19

Eur Rev Med Pharmacol Sci
Year: 2020
Vol. 24 - N. 22
Pages: 11953-11959
DOI: 10.26355/eurrev_202011_23856